Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma (IMbrave150 and Korean patients cohorts)

被引：0
|
作者：
Chon, H. [1 ]
Song, Y. S. [2 ]
Yang, H. [3 ]
Kim, I. [4 ]
Hye-Young, K. [5 ]
Lee, W. S. [6 ]
Sang, Y. B. [7 ]
Kim, C. [8 ]
机构：
[1] Bundang Cha Med Ctr, Med Oncol, Seongnam, South Korea
[2] CHA Bundang Med Ctr, Div Endocrinol & Metabolsim, Seongnam, South Korea
[3] Bundang Cha Med Ctr, Oncol, Seongnam, South Korea
[4] Inje Univ, Med Oncol, Haeundae Paik Hosp, Busan, South Korea
[5] Ulsan Univ Hosp, Med oncol, Ulsan, South Korea
[6] Bundang Cha Med Ctr, Lab Translat Immunooncol, Seongnam, South Korea
[7] CHA Bundang Med Ctr, Hematol & Oncol, Seongnam, South Korea
[8] Bundang Cha Med Ctr, Dept Med Oncol, Seongnam, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
基金：
新加坡国家研究基金会;
关键词：
D O I：
10.1016/j.annonc.2023.09.2137
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
993P
引用
收藏
页码：S611 / S611
页数：1
相关论文
共 50 条
  • [31] Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma
    Han, Ji Won
    Jang, Jeong Won
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (14)
  • [32] IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma-An Exploratory Analysis of the Phase III Study
    Kudo, Masatoshi
    Finn, Richard S. S.
    Galle, Peter R. R.
    Zhu, Andrew X. X.
    Ducreux, Michel
    Cheng, Ann-Lii
    Ikeda, Masafumi
    Tsuchiya, Kaoru
    Aoki, Ken-ichi
    Jia, Jing
    Lencioni, Riccardo
    LIVER CANCER, 2023, 12 (03) : 238 - 250
  • [33] IMbrave150: EXPLORATORY EFFICACY AND SAFETY OF ATEZOLIZUMAB (ATEZO) plus BEVACIZUMAB (BEV) VS SORAFENIB (SOR) IN PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WITH NON-VIRAL ETIOLOGY IN A GLOBAL PHASE III STUDY
    Zhu, Andrew X.
    Finn, Richard
    Ducreux, Michel
    Hu, Youyou
    Sommer, Nicolas
    Verret, Wendy
    Kulik, Laura M.
    Galle, Peter R.
    HEPATOLOGY, 2021, 74 : 646A - 647A
  • [34] Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial (vol 11, pg 558, 2022)
    Li
    LIVER CANCER, 2023, 12 (04) : 392 - 393
  • [35] IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Mertens, Joachim
    Kim, Tae-You
    Kudo, Masatoshi
    Lim, Ho Yeong
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed
    Li, Daneng
    Feng, Yin-Hsun
    Verret, Wendy
    Nicholas, Alan
    Li, Lindong
    Ma, Ning
    Zhu, Andrew X.
    Cheng, Ann-Lii
    SWISS MEDICAL WEEKLY, 2021, 151 : 25 - 26
  • [36] IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC).
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Kim, Tae-You
    Kudo, Masatoshi
    Lim, Ho Yeong
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed
    Li, Daneng
    Feng, Yin-Hsun
    Verret, Wendy
    Nicholas, Alan
    Li, Lindong
    Ma, Ning
    Zhu, Andrew X.
    Cheng, Ann-Lii
    CANCER RESEARCH, 2021, 81 (13)
  • [37] Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma
    Cheon, Jaekyung
    Yoo, Changhoon
    Hong, Jung Yong
    Kim, Han Sang
    Lee, Dae-Won
    Lee, Myung Ah
    Kim, Jin Won
    Kim, Ilhwan
    Oh, Sang-Bo
    Hwang, Jun-Eul
    Chon, Hong Jae
    Lim, Ho Yeong
    LIVER INTERNATIONAL, 2022, 42 (03) : 674 - 681
  • [38] Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
    Galle, Peter R.
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Zhu, Andrew X.
    Kim, Tae-You
    Kudo, Masatoshi
    Breder, Valeriy Vladimirovich
    Merle, Philippe
    Kaseb, Ahmed Omar
    Li, Daneng
    Mulla, Sohail
    Verret, Wendy
    Xu, Derek-Zhen
    Hernandez, Sairy
    Liu, Juan
    Huang, Chen
    Lim, Ho Yeong
    Cheng, Ann-Lii
    Ducreux, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [39] HEPATIC EVENTS AND VIRAL KINETICS IN PATIENTS (PTS) WITH HEPATITIS B/C VIRUS (HBV/HCV)-RELATED, UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) TREATED WITH ATEZOLIZUMAB (ATEZO) plus BEVACIZUMAB (BEV) OR SORAFENIB (SOR) IN IMbrave150
    Hsu, Chiun
    Ducreux, Michel
    Zhu, Andrew X.
    Qin, Shukui
    Ikeda, Masafumi
    Kim, Tae-You
    Galle, Peter R.
    Finn, Richard
    Chen, Ethan
    Shao, Hui
    Stanzel, Sven Franz
    Xu, Derek-Zhen
    Cheng, Ann-Lii
    HEPATOLOGY, 2020, 72 : 779A - 780A
  • [40] IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor).
    Ducreux, Michel
    Zhu, Andrew X.
    Cheng, Ann-Lii
    Galle, Peter R.
    Ikeda, Masafumi
    Nicholas, Alan
    Verret, Wendy
    Li, Lindong
    Gaillard, Vincent E.
    Lencioni, Riccardo
    Finn, Richard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345